Literature DB >> 23661661

Critical upper airway obstruction in sporadic angioedema responding to C1-esterase inhibitor.

Andrew W O'Keefe1, Christine McCusker, Moshe Ben-Shoshan.   

Abstract

We describe a case of recurrent oropharyngeal angioedema in a 16-year-old boy with a history of sickle cell disease and thrombocytopenia and with no family history of angioedema. Emergency treatment of angioedema with C1-esterase inhibitor (C1-INH) provided immediate relief, avoiding the placement of a surgical airway. Further evaluation has shown C1-INH to be normal in quantity and function, with normal complement studies during acute attacks. Genetic testing revealed no abnormality in the factor XII gene. Our case exemplifies that even in cases of sporadic angioedema, treatment with C1-INH may be an effective and life-saving management strategy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23661661      PMCID: PMC3669871          DOI: 10.1136/bcr-2013-009616

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  8 in total

1.  Successful C1 esterase inhibitor therapy in a child with a novel type 3 hereditary angioedema-like syndrome.

Authors:  Janet L Rasmussen; Miguel A Park; Philip R Fischer
Journal:  Ann Allergy Asthma Immunol       Date:  2012-04-21       Impact factor: 6.347

Review 2.  Current management options for hereditary angioedema.

Authors:  Konrad Bork
Journal:  Curr Allergy Asthma Rep       Date:  2012-08       Impact factor: 4.806

3.  Successful perioperative management of a patient with C1 esterase inhibitor deficiency with a novel bradykinin receptor B2 antagonist.

Authors:  K T Senaratne; A M Cottrell; R I Prentice
Journal:  Anaesth Intensive Care       Date:  2012-05       Impact factor: 1.669

4.  Type III hereditary angio-oedema: clinical and biological features in a French cohort.

Authors:  V Vitrat-Hincky; A Gompel; C Dumestre-Perard; I Boccon-Gibod; C Drouet; J Y Cesbron; J Lunardi; C Massot; L Bouillet
Journal:  Allergy       Date:  2010-04-07       Impact factor: 13.146

5.  Clinical efficacy of icatibant in the treatment of acute hereditary angioedema during the FAST-3 trial.

Authors:  Murat Baş
Journal:  Expert Rev Clin Immunol       Date:  2012-11       Impact factor: 4.473

Review 6.  An update on hereditary angioedema.

Authors:  Derek Hsu; Marcus Shaker
Journal:  Curr Opin Pediatr       Date:  2012-10       Impact factor: 2.856

Review 7.  Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part I. Classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis.

Authors:  T Caballero; M L Baeza; R Cabañas; A Campos; S Cimbollek; C Gómez-Traseira; T González-Quevedo; M Guilarte; G J Jurado-Palomo; J I Larco; M C López-Serrano; M López-Trascasa; C Marcos; J M Muñoz-Caro; M Pedrosa; N Prior; M Rubio; A Sala-Cunill
Journal:  J Investig Allergol Clin Immunol       Date:  2011       Impact factor: 4.333

8.  Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor.

Authors:  Konrad Bork
Journal:  Allergy Asthma Clin Immunol       Date:  2010-07-28       Impact factor: 3.406

  8 in total
  2 in total

Review 1.  Primary immunodeficiency for the primary care provider.

Authors:  A W O'Keefe; M Halbrich; M Ben-Shoshan; C McCusker
Journal:  Paediatr Child Health       Date:  2016-03       Impact factor: 2.253

Review 2.  Efficacy of Treatment of Non-hereditary Angioedema.

Authors:  Mignon van den Elzen; M F C L Go; A C Knulst; M A Blankestijn; H van Os-Medendorp; H G Otten
Journal:  Clin Rev Allergy Immunol       Date:  2018-06       Impact factor: 8.667

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.